Anbio Biotechnology (NNNN) Net margin 2022–2025
Anbio Biotechnology (NNNN) net profit margin by fiscal year — reported net income divided by reported revenue.
74.1%FY2025 · since FY2022: 42.5% → 74.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 74.1% | +45.1 pp |
| FY2024 | 29.0% | -4.6 pp |
| FY2023 | 33.6% | -8.9 pp |
| FY2022 | 42.5% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More NNNN financial trends
NNNN RevenueNNNN Net incomeNNNN Gross profitNNNN Gross marginNNNN Operating incomeNNNN Operating marginNNNN Operating cash flowNNNN Free cash flowNNNN Capital expendituresNNNN Return on equityNNNN Stock buybacksNNNN Dividends paidNNNN Total assetsNNNN Total liabilitiesNNNN Shareholders’ equityNNNN overview →